导师风采
方仪
个人信息
Personal Information
- 性别：男
- 导师类型：博士生导师
- 职称：主任医师
- 该职称任职时间：20171201
联系方式
Contact Information
- 所属院系：肿瘤医院
- 所属专业：
- 邮箱 : fangyi@cicams.ac.cn
- 工作电话 : 010-87787678
个人简介
Personal Profile
方仪，中国医学科学院肿瘤医院乳腺外科主任医师，临床医学博士，曾任北京市朝阳区三环肿瘤医院副院长，致力于乳腺癌外科治疗及相关基础研究，尤其擅长肿瘤整形、乳腺癌术后乳房即刻重建等术式。近五年主持国家自然科学基金面上项目1项，科技创新2030-“新一代人工智能”重大项目课题1项，北京市自然科学基金面上项目1项，北京市科学技术委员会科技计划项目1项，中国医学科学院医学与健康创新工程1项，院所科研课题1项；以第一或通讯作者在国内外期刊发表学术论文30余篇，最高影响因子37.4分，以第一申请人申请发明专利一项，实用新型专利两项。学术兼职包括中国医疗保健国际交流促进会乳腺疾病分会秘书长、中国抗癌协会乳腺癌专业委员会青年委员、中国人体健康科技促进会生育力保护与保存专业委员会副主任委员、北京乳腺病防治学会国际医疗与合作专业委员会/健康管理专业委员会常委、北京癌症防治学会副主任委员、北京肿瘤病理精准诊断研究会/青委会副主任委员等职务。
团队简介
Team Profile
待补充更新
- 研究方向Research Directions
乳腺癌综合治疗,乳腺癌相关基础研究,乳腺肿瘤整形修复技术
- 在校研究生Current Graduate Students
硕士研究生 0 名，博士研究生 5 名
- 科研项目Research Projects
| # | 项目名称 | 起止日期 | 金额 | 项目类型 | 本人角色 |
|---|---|---|---|---|---|
| 1 | 去泛素化酶OTUD6B通过调控MDM2/FOXO3a促进三阴性乳腺癌生长及侵袭转移的机制研究 | 2021-01-01 —— 2024-12 | 55.0 | 主持在研的国家或省部级科研项目 | 主持者 |
- 发表论文Papers
| # | 论文题目 | 期刊名称 | 发表年份 | 论文署名 |
|---|---|---|---|---|
| 1 | Molecular and Clinical Characterization of PD-1 in Breast Cancer Using Large-Scale Transcriptome Data | Frontiers in Immunology | 2021-06 | 通讯作者 |
| 2 | Research Progress Concerning Dual Blockade of Lymphocyte-Activation Gene 3 and Programmed Death- 1/Programmed Death-1 Ligand-1 Blockade in Cancer Immunotherapy: Preclinical and Clinical Evidence of This Potentially More Effective Immunotherapy Strategy | Frontiers in Immunology | 2021-01 | 通讯作者 |
| 3 | Oncotype DX Breast Recurrence Score Distribution and Chemotherapy Benefit Among Women of Different Age Groups with HR-Positive, HER2-Negative, Node-Negative Breast Cancer in the SEER Database | Frontiers in Oncology | 2020-10 | 通讯作者 |
| 4 | 外周血中常见血液学参数对乳腺癌预后评估价值的研究进展 | 现代生物医学进展 | 2022-06-07 | 通讯作者 |
| 5 | Artificial intelligence: a key to relieve China's insufficient and unequally-distributed medical resources | American Journal of Translational Research | 2019-05 | 通讯作者 |
| 6 | Recent Advances in UnderstandingFOXN3 in Breast Cancer, and OtherMalignancies | Frontiers in Oncology | 2019-05 | 通讯作者 |
| 7 | 男性乳腺癌的临床病理特征及生存分析 | 临床肿瘤学杂志 | 2022-06-06 | 通讯作者 |
| 8 | Prognostic Nutritional Index (PNI) in Patients With Breast Cancer Treated With Neoadjuvant Chemotherapy as a Useful Prognostic Indicator | Frontiers in Cell and Developmental Biology | 2021-03 | 通讯作者 |
| 9 | Letter regarding Sopik V et al. entitled "Impact of microinvasion on breast cancer mortality in women with ductal carcinoma in situ". | Breast Cancer Research and Treatment | 2019-11 | 通讯作者 |
| 10 | ESTIMATE algorithm is no appropriate for inferring tumor purity and？stromal and？immune cell admixture in？hematopoietic or？stromal tumors | Cancer Immunology Immunotherapy | 2020-06 | 通讯作者 |
| 11 | Pre-treatment systemic immune-inflammation index is a useful prognostic indicator in patients with breast cancer undergoing neoadjuvant chemotherapy | Journal of Cellular of Molecular Medicine | 2020-03 | 通讯作者 |
| 12 | Variation in Breast Cancer Subtype Incidence and Distribution by Race/Ethnicity in the United States from 2010 to 2015 | JAMA Network Open | 2020-10 | 通讯作者 |
| 13 | Comprehensive Analysis of the Expression and Prognosis for TDO2 in Breast Cancer | Molecular Therapy-Oncolytics | 2020-03 | 通讯作者 |
| 14 | Omitting ALND Is Not Safe for a Cohort of Early-Stage Breast Cancer Patients with 1-2 SLNs Macro-Metastases and Breast-Conserving Therapy: A Single-Center Retrospective Study | Iranian Journal Public Health | 2020-07 | 通讯作者 |
| 15 | Factors associated with chemotherapy beneft in breast cancer patients with midrange oncotype DX breast recurrence scores | Cancer Letters | 2021-04 | 通讯作者 |
| 16 | Risk factors and a predictive nomogram for non-sentinel lymph node metastases in Chinese breast cancer patients with one or two sentinel lymph node macrometastases and mastectomy | Current Oncology | 2022-06-07 | 通讯作者 |
| 17 | Immunological Therapy: A Novel Thriving Area for Triple Negative Breast Cancer Treatment. | Cancer Letters | 2022-06-07 | 通讯作者 |
| 18 | Pretreatment Systemic Inflammation Response Index in Patients with Breast Cancer Treated with Neoadjuvant Chemotherapy as a Useful Prognostic Indicator | Cancer Management and Research | 2020-03 | 通讯作者 |
| 19 | Mechanism of trastuzumab resistance caused by HER-2 mutation in breast carcinomas | Cancer Management and Research | 2022-06-07 | 通讯作者 |
| 20 | Nanomedicines inhibiting tumor metastasis and recurrence and their clinical applications | Nano Today | 2020-11 | 通讯作者 |
| 21 | Identification of the Significant Genes Regulated by Estrogen Receptor in Estrogen Receptor-Positive Breast Cancer and Their Expression Pattern Changes When Tamoxifen or Fulvestrant Resistance Occurs | Frontiers in Genetics | 2022-06-07 | 通讯作者 |
| 22 | Melatonin: A Potential Therapeutic Option for Breast Cancer | Trends in Endocrinology and Metabolism | 2020-11 | 通讯作者 |
| 23 | Recent Progress for the Techniques of MRI-Guided Breast Interventions and their applications on SurgicaL Strategy | Journal of Cancer | 2020-05 | 通讯作者 |
| 24 | Expression signatures and roles of microRNAs in inflammatory breast cancer | Cancer Cell International | 2022-06-07 | 通讯作者 |
| 25 | Conditional Survival of female patients with operable invasive Breast Cancer in US: A population-based study | Journal of Cancer | 2022-06-07 | 通讯作者 |
| 26 | A Novel Prognostic Signature of mRNA-lncRNA in Breast Cancer | DNA and Cell Biology | 2020-02 | 通讯作者 |
| 27 | Prognostic Alternative mRNA Splicing Signature and a Novel Biomarker in Triple-Negative Breast Cancer | DNA and Cell Biology | 2020-06 | 通讯作者 |
| 28 | The Prognostic Significance of Anisomycin-Activated Phospho-c-Jun NH2-Terminal Kinase (p-JNK) in Predicting Breast Cancer Patients' Survival Time | Frontiers in Cell and Developmental Biology | 2022-06-06 | 通讯作者 |
| 29 | HER2 and PTEN as Predictive Markers for Breast Cancer Neoadjuvant Chemotherapy with Anthracycline Plus Paclitaxel | Journal of Biomaterials and Tissue Engneering | 2022-06-06 | 通讯作者 |
| 30 | LINC01355 suppresses breast cancer growth through FOXO3-mediated transcriptional repression of CCND1. | Cell Death & Disease | 2019-06 | 通讯作者 |
| 31 | Quantitative phosphoproteomics reveals genistein as a modulator of cell cycle and DNA damage respones pathways in triple-negative breast cancer cells | International Journal of Oncology | 2022-06-06 | 通讯作者 |
| 32 | 乳腺癌术后即刻背阔肌肌皮瓣/肌瓣乳房重建术研究进展 | 中华实用诊断与治疗杂志 | 2022-06-06 | 通讯作者 |
| 33 | Comparisons of Therapeutic and Aesthetic Effects of One-Stage Implant-Based Breast Reconstruction with and without Biological Matrix | Cancer Management and Research | 2020-12 | 通讯作者 |
| 34 | Incidence, risk factors, prevention and treatment of postmastectomy pain syndrome in breast cancer： A multicenter study | International Journal of Surgery | 2022-10 | 通讯作者 |
| 35 | The Causal Effect of Dietary Composition on the Risk of Breast Cancer：A Mendelian Randomizaiton Study | Nutrients | 2023-05 | 通讯作者 |
| 36 | Controlling Nutritional Status (CONUT) as a Novel Postoperative Prognostic Marker in Breast Cancer Patients: A Retrospective Study | Biomed Research International | 2022-12 | 通讯作者 |
| 37 | Revolutionizing the battle against locally advanced breast cancer: A comprehensive insight into neoadjuvant radiotherapy | MEDICINAL RESEARCH REVIEWS | 2024-03 | 通讯作者 |
| 38 | Toxicities associated with immune checkpoint inhibitors: a systematic study | International Journal of Surgery | 2023-06 | 通讯作者 |
| 39 | Trends in cancer-related suicide in the United States: a population-based epidemiology study spanning 40 years of data | Translational Psychiatry | 2024-05 | 通讯作者 |
| 40 | The Systemic Immune-inflammation Index is an Independent Predictor of Survival in Breast Cancer Patients | Cancer Management and Research | 2022-02 | 通讯作者 |
| 41 | Subsequent risk of suicide among 9,300,812 cancer survivors in US: A population-based cohort study covering 40 years of data | EClinicalMedicine | 2022-02 | 通讯作者 |
| 42 | MS4A1 as a Potential Independent Prognostic Factors of Breast cancer Related to Lipid Metabolism and Immune Microenvironment | MEDICAL SCIENCE MONITOR | 2022-01 | 通讯作者 |
| 43 | Patient-Reported Outcomes and Complications following Breast Reconstruction: A Comparison between Biological Matrix-Assisted Direct to-Implant and Latissimus Dorsi Flap | Frontiers in Oncology | 2022-01 | 通讯作者 |
| 44 | Prognostic Value and Clinical Significance of LIPH in Breast Cancer | International Journal of General Medicine | 2021-11 | 通讯作者 |
| 45 | "Efficacy and Safety of Anti-PD-1/ PD-L1 Monotherapy for Metastatic Breast Cancer: Clinical Evidence | Frontiers in Pharmacology | 2021-06 | 通讯作者 |
| 46 | Management of Adenoid Cystic Carcinoma of the Breast:A Single-Institution Study | Frontiers in Oncology | 2021-03 | 通讯作者 |
- 科研获奖Research Awards
无
- 研究成果Research Findings
| # | 成果类型 | 项目/专利/新品种名称 |
|---|---|---|
| 1 | 作为主创人员获得授权的发明专利和新品种 | 一种乳腺癌术后复发风险检测方法 |
| 2 | 作为主创人员获得授权的发明专利和新品种 | 用于乳腺外科手术和乳腺整形外科手术的牵拉钳 |
| 3 | 作为主创人员获得授权的发明专利和新品种 | 用于乳腺外科手术和乳腺整形外科手术的牵拉钳 |
| 4 | 作为主创人员获得授权的发明专利和新品种 | 用于乳腺外科术中皮瓣牵拉钳的牵拉杆 |
| 5 | 作为主创人员获得授权的发明专利和新品种 | 手术用拉钩 |
| 6 | 作为主创人员获得授权的发明专利和新品种 | 医用注射器 |
| 7 | 作为主创人员获得授权的发明专利和新品种 | 用于乳腺外科手术和乳腺整形外科手术的牵钩 |
| 8 | 出版高水平专著 | 专家教你呵护乳腺健康 |